Pacific Blue™ anti-mouse CD4 Antibody

Pricing & Availability
Clone
GK1.5 (See other available formats)
Regulatory Status
RUO
Other Names
L3T4, T4
Isotype
Rat IgG2b, κ
Ave. Rating
Submit a Review
Product Citations
publications
GK1dot5_Blue_091207
C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) Pacfic Blue™ (filled histogram) or rat IgG2b, κ Pacific Blue™ isotype control (open histogram).
  • GK1dot5_Blue_091207
    C57BL/6 mouse splenocytes were stained with CD4 (clone GK1.5) Pacfic Blue™ (filled histogram) or rat IgG2b, κ Pacific Blue™ isotype control (open histogram).
See Pacific Blue™ spectral data
Cat # Size Price Quantity Check Availability Save
100427 25 µg $85.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
100428 100 µg $195.00
Check Availability


Need larger quantities of this item?
Request Bulk Quote
Description

CD4 is a 55 kD protein also known as L3T4 or T4. It is a member of the Ig superfamily, primarily expressed on most thymocytes, a subset of T cells, and weakly on macrophages and dendritic cells. It acts as a coreceptor with the TCR during T cell activation and thymic differentiation by binding MHC class II and associating with the protein tyrosin kinase, lck.

Product Details
Technical data sheet

Product Details

Reactivity
Mouse
Antibody Type
Monoclonal
Host Species
Rat
Immunogen
Mouse CTL clone V4
Formulation
Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation
The antibody was purified by affinity chromatography, and conjugated with Pacific Blue™ under optimal conditions.
Concentration
0.5 mg/ml
Storage & Handling
The CD4 antibody solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application

FC - Quality tested

Recommended Usage

Each lot of this antibody is quality control tested by immunofluorescent staining with flow cytometric analysis. The suggested use of this reagent is ≤1.0 µg per 106 cells in 100 µl volume. It is highly recommended that the reagent be titrated for optimal performance for each application.

* Pacific Blue™ has a maximum emission of 455 nm when it is excited at 405 nm. Prior to using Pacific Blue™ conjugate for flow cytometric analysis, please verify your flow cytometer's capability of exciting and detecting the fluorochrome.


Alexa Fluor® and Pacific Blue™ are trademarks of Life Technologies Corporation.

View full statement regarding label licenses
Excitation Laser
Violet Laser (405 nm)
Application Notes

Additional reported applications (for the relevant formats) include: blocking of CD4+ T cell activation1,4,11, thymocyte costimulation3, in vitro and in vivo depletion2,5-8, blocking of egg-sperm cell adhesion1,4, immunohistochemical staining of acetone-fixed frozen sections9,10, and immunoprecipitation1,2. The GK1.5 antibody is able to block CD4 mediated cell adhesion and T cell activation. Binding of GK1.5 antibody to CD4 T cells can be blocked by RM4-5 antibody, but not RM4-4 antibody. For in vivo studies or highly sensitive assays, we recommend Ultra-LEAF™ purified antibody (Cat. No. 100442) with a lower endotoxin limit than standard LEAF™ purified antibodies (Endotoxin < 0.01 EU/µg).

Application References

(PubMed link indicates BioLegend citation)
  1. Dialynas DP, et al. 1983. J. Immunol. 131:2445. (Block, IP)
  2. Dialynas DP, et al. 1983. Immunol. Rev. 74:29. (IP, Deplete)
  3. Wu L, et al. 1991. J. Exp. Med. 174:1617. (Costim)
  4. Godfrey DI, et al. 1994. J. Immunol. 152:4783. (Block)
  5. Gavett SH, et al. 1994. Am. J. Respir. Cell. Mol. Biol. 10:587. (Deplete)
  6. Schuyler M, et al. 1994. Am. J. Respir. Crit. Care Med. 149:1286. (Deplete)
  7. Ghobrial RR, et al. 1989. Clin. Immunol. Immunopathol. 52:486. (Deplete)
  8. Israelski DM, et al. 1989. J. Immunol. 142:954. (Deplete)
  9. Zheng B, et al. 1996. J. Exp. Med. 184:1083. (IHC)
  10. Frei K, et al. 1997. J. Exp. Med. 185:2177. (IHC)
  11. Felix NJ, et al. 2007. Nat. Immunol. 8:388. (Block)
Product Citations
  1. Borkner L, et al. 2017. J Immunol. 10.4049/jimmunol.1602115. PubMed
  2. Vacca M, et al. 2017. Front Immunol. . 10.3389/fimmu.2017.01462. PubMed
  3. Hsieh WC, et al. 2018. Nat Commun. 9:463. PubMed
  4. Liu S, et al. 2018. Front Immunol. 29:208. PubMed
  5. Wang Z et al. 2018. Immunity. 49(1):80-92 . PubMed
  6. Lu Y, et al. 2018. Cancer Cell. 33:1048. PubMed
  7. Bing Wu et al. 2018. Immunity. 49(5):886-898 . PubMed
  8. Thwe PM et al. 2017. Cell metabolism. 26(3):558-567 . PubMed
  9. Zhao J, et al. 2019. Nat Commun. 10:899. PubMed
  10. Zhou J, et al. 2019. Nat Commun. 10:2427. PubMed
  11. Kobayashi S, et al. 2019. J Immunol. 203:1447. PubMed
  12. Tian D, et al. 2019. Nat Commun. 10:4246. PubMed
  13. Dangaj D, et al. 2019. Cancer Cell. 35:885. PubMed
  14. Komuczki J, et al. 2019. Immunity. 50:1289. PubMed
  15. Zheng X, et al. 2019. PLoS Pathog. 15:e1008036. PubMed
  16. Brenner E, et al. 2020. Nat Commun. 11:1335. PubMed
  17. Ma Y, et al. 2020. Cell Prolif. 53:e12802. PubMed
  18. Vono M, et al. 2020. Cell Reports. 28(7):1773-1784.e5.. PubMed
  19. Teo T, et al. 2013. J Immunol. 190:259. PubMed
  20. Dekhtiarenko I, et al. 2013. J Immunol. 190:3399. PubMed
  21. Morawski P, et al. 2013. J Biol Chem. 288:24494. PubMed
  22. Wong L, et al. 2013. J Biol Chem. 288:35170. PubMed
  23. Eitas T, et al. 2014. J Biol Chem. 289:4173. PubMed
  24. Sawant D, et al. 2014. J Immunol. 192:2904. PubMed
  25. Madireddi S, et al. 2014. J Exp Med. 211:1433. PubMed
  26. MaruYama T 2015. Biochem Biophys Res Commun. 464: 586-589. PubMed
  27. MaruYama T, et al. 2015. J Leukoc Biol. 98: 385-393. PubMed
  28. Price J, et al. 2015. Diabetes. 64: 3521 - 3531. PubMed
  29. Guo Z, et al. 2016. Nat Commun. 7:10307. PubMed
  30. Baglaenko Y, et al. 2016. PLoS One. 11: 0150515. PubMed
  31. Nicolay N, et al. 2016. Sci Rep. 6: 26645. PubMed
  32. Uhde A, et al. 2016. PLoS One. 11: 0161883. PubMed
  33. Miyauchi K, et al. 2016. Nat Immunol. 17:1447-1458. PubMed
  34. Dekhtiarenko I, et al. 2016. PLoS Pathog. 12:e1006072. PubMed
  35. Cerina M, et al. 2017. Brain Behav Immun. 59:103-117. PubMed
  36. Simoni L, et al. 2020. Cell Rep. 33:108330. PubMed
  37. Bogie JF, et al. 2020. Ther Adv Chronic Dis. 11:2040622320947378. PubMed
  38. Dumas AA, et al. 2020. EMBO J. 39:e103790. PubMed
  39. Lutes LK, et al. 2021. eLife. 10:00. PubMed
  40. Glassman CR, et al. 2021. eLife. 10:00. PubMed
  41. Lebratti T, et al. 2021. eLife. 10:00. PubMed
  42. Ang QY, et al. 2020. Cell. 181(6):1263-1275.e16. PubMed
  43. Alissafi T, et al. 2020. Cell Metabolism. 32(4):591-604.e7. PubMed
  44. Jiang L, et al. 2020. Cell. 183(5):1219-1233.e18. PubMed
  45. Nayak RR, et al. 2021. Cell Host Microbe. 29(3):362-377.e11. PubMed
  46. Wu B, et al. 2021. Immunity. 54(2):308-323.e6. PubMed
  47. Heyde A, et al. 2021. Cell. 184(5):1348-1361.e22. PubMed
  48. Daneshmandi S, et al. 2021. Cell Reports. 34(10):108831. PubMed
  49. Bruand M, et al. 2021. Cell Reports. 36(3):109412. PubMed
  50. Zhang L, et al. 2020. Cell. 442:181. PubMed
  51. Castiello MC, et al. 2020. J Allergy Clin Immunol. . PubMed
  52. Picard M, et al. 2020. Cell Death Differ. . PubMed
  53. Zhang Y, et al. 2021. Commun Biol. 344:4. PubMed
  54. Yin Q, et al. 2021. Proc Natl Acad Sci U S A. 118: . PubMed
  55. Parodi B, et al. 2021. Front Immunol. 12:655212. PubMed
RRID
AB_493646 (BioLegend Cat. No. 100427)
AB_493647 (BioLegend Cat. No. 100428)

Antigen Details

Structure
Ig superfamily, 55 kD
Distribution

Majority of thymocytes, T cell subset

Function
TCR co-receptor, T cell activation
Ligand/Receptor
MHC class II molecule
Cell Type
Dendritic cells, T cells, Thymocytes, Tregs
Biology Area
Immunology
Molecular Family
CD Molecules
Antigen References

1. Barclay A, et al. 1997. The Leukocyte Antigen FactsBook Academic Press.
2. Bierer BE, et al. 1989. Annu. Rev. Immunol. 7:579.
3. Janeway CA. 1992. Annu. Rev. Immunol. 10:645.

Gene ID
12504 View all products for this Gene ID
UniProt
View information about CD4 on UniProt.org

Related FAQs

I am unable to see expression of T cell markers such as CD3 and CD4 post activation.
TCR-CD3 complexes on the T-lymphocyte surface are rapidly downregulated upon activation with peptide-MHC complex, superantigen or cross-linking with anti-TCR or anti-CD3 antibodies. PMA/Ionomycin treatment has been shown to downregulate surface CD4 expression. Receptor downregulation is a common biological phenomenon and so make sure that your stimulation treatment is not causing it in your sample type.
Go To Top Version: 1    Revision Date: 11/30/2012

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

 

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

 

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587

This data display is provided for general comparisons between formats.
Your actual data may vary due to variations in samples, target cells, instruments and their settings, staining conditions, and other factors.
If you need assistance with selecting the best format contact our expert technical support team.

ProductsHere
Insert Note Here
Save Close Clear
Lab Timer
Tools
Login/Register
Remember me
Forgot your password? Reset Password
Request an Account